SecBot SecBot
Biotech Drug Report Generated Oct 27, 2026

votoplam

NVS·NOVARTIS AG
MIXED
Drug Impact Rating2/10
Trial phase
Phase 3
Time to market
At least 4-5 years, assuming Phase 3 success and regulatory filing around 2030-2031
Why 2/10
No hard dated catalyst exists within the next ~12 months: the Phase 3 INVEST-HD trial (NCT07326709) began enrolling in March 2026, targets 770 patients, and has an estimated primary completion date of April 2030. For Novartis, a $200B+ diversified pharma with dozens of marketed drugs, votoplam is a small pipeline component, so even a distant readout would not be a company-defining event.
Actionable Insight MIXED

The next hard catalyst is the Phase 3 INVEST-HD topline readout, expected around 2030, roughly 3+ years away. For Novartis, a $200B+ diversified pharma, votoplam is one of many pipeline assets; the readout is too distant and too small a concentration to drive a major share-price move. Watch for interim updates at medical conferences (e.g., 2027-2028) and any regulatory pathway clarity (accelerated approval discussions), but near-term stock movement from this drug alone is unlikely.

Price Chart

Loading chart...

Executive Summary

Votoplam (formerly PTC518/HTT227) is an investigational oral small-molecule HTT splicing modifier being developed by Novartis for Huntington's disease (HD), a fatal genetic neurodegenerative disorder with no approved disease-modifying therapies. In December 2024, Novartis paid PTC Therapeutics $1B upfront (up to $2.9B total) to license the program. Phase 2 PIVOT-HD data showed statistically significant huntingtin protein reduction (p<0.0001), and 24-month extension data reported in April 2026 showed 52% slowing of disease progression at the 10mg dose versus a natural-history cohort. The Phase 3 INVEST-HD trial (NCT07326709) began enrolling 770 patients in March 2026, with a primary completion date estimated in April 2030. Roche's competing HD programs (tominersen, RG6496) were discontinued in July 2026, narrowing the competitive field. For Novartis, votoplam is a small pipeline asset within a $200B+ diversified pharma; the distant readout timeline and low concentration mean it is unlikely to be a near-term stock driver.

How It Works

Votoplam is a daily pill that works by modifying how the HTT gene's instructions are spliced, reducing the production of the toxic huntingtin protein that causes Huntington's disease. It is designed to slow or stop disease progression rather than just treat symptoms.

Trial Status

The Phase 3 INVEST-HD trial (NCT07326709) began enrolling in March 2026, is currently recruiting at 117 sites across 27 countries, and targets 770 participants with early symptomatic HD. Estimated primary completion is April 2030. Phase 2 PIVOT-HD met its primary endpoint, and a 24-month interim analysis of the long-term extension showed dose-dependent slowing of disease progression.

The Two-Sided Case

▲ Bull Case5
Phase 2 PIVOT-HD met its primary endpoint with highly significant HTT protein reduction (p<0.0001) at Week 12, showing 23% reduction at 5mg and 36-39% at 10mg.
24-month extension data showed dose-dependent slowing of disease progression: 52% at 10mg and 28% at 5mg on cUHDRS vs a matched natural-history cohort, the strongest signal seen in an HD disease-modifying trial.
Novartis validated the asset with a $1B upfront payment (up to $2.9B total), one of the largest neurology licensing deals, signaling high internal conviction.
Roche discontinued both its HD programs (tominersen and RG6496) in July 2026, narrowing the competitive field and positioning votoplam as a potential first-to-market oral disease-modifying therapy.
Only symptomatic chorea treatments exist (Xenazine, Austedo, Ingrezza); no disease-modifying drug is approved for HD, representing a large unmet need and commercial opportunity.
▼ Bear Case5
Phase 3 readout is not expected until ~2030, a distant, high-risk binary with no near-term catalyst for Novartis shares.
The Phase 2 data used a natural-history external control arm, not a concurrent placebo, which raises the bar for Phase 3 confirmation.
Huntington's disease trials have a history of failure (Roche's tominersen and RG6496 were both discontinued in July 2026), and disease-modifying endpoints remain unvalidated.
For Novartis, votoplam is a tiny fraction of a $40B+ revenue base; even a positive readout would have limited impact on the stock.
Novartis paid $1B upfront, a sunk cost that does not guarantee returns; the deal includes up to $1.9B in milestones, adding future financial obligations.

Upcoming Catalysts

  • Phase 3 INVEST-HD topline readout (estimated ~2030), the pivotal efficacy/safety data
  • Potential interim data presentations at medical conferences (e.g., 2027-2028)
  • Any FDA discussions on accelerated approval pathway (no public updates as of Oct 2026)

Source Filing

The SecBot filing or press-release report that triggered this drug report:

NOVARTIS AG 6-K NVS ·Originating report

Sources · 12

Hover a chip for the title
1 novartis.com2 ir.ptcbio.com3 ir.ptcbio.com4 biospace.com5 huntington-disease.org6 clinicaltrials.gov7 pharmaphorum.com8 fiercebiotech.com9 synapse.patsnap.com10 adisinsight.springer.com11 rarediseaseadvisor.com12 novartis.com